Handelsbanken Fonder AB Acquires 3,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Handelsbanken Fonder AB raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,600 shares of the company’s stock after buying an additional 3,000 shares during the period. Handelsbanken Fonder AB’s holdings in Apellis Pharmaceuticals were worth $976,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of APLS. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at approximately $402,000. Pallas Capital Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at approximately $384,000. Sippican Capital Advisors grew its position in shares of Apellis Pharmaceuticals by 30.8% in the third quarter. Sippican Capital Advisors now owns 30,313 shares of the company’s stock valued at $874,000 after purchasing an additional 7,135 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at approximately $1,370,000. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 13,551 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $412,356.93. Following the completion of the transaction, the chief executive officer now owns 418,519 shares of the company’s stock, valued at $12,735,533.17. The trade was a 3.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on APLS. Wells Fargo & Company decreased their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Citigroup decreased their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Needham & Company LLC decreased their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $26.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, January 29th. Finally, Piper Sandler reduced their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.71.

Apellis Pharmaceuticals Trading Down 1.3 %

Shares of APLS stock opened at $26.00 on Friday. The stock’s fifty day moving average price is $30.18 and its two-hundred day moving average price is $31.66. The company has a market cap of $3.23 billion, a PE ratio of -12.81 and a beta of 0.96. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $70.45. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).